Coeptis Therapeutics (NASDAQ:ZSQR) Trading Down 9% – Time to Sell?

Shares of Coeptis Therapeutics Holdings, Inc. (NASDAQ:ZSQR) dropped 9% during trading on Wednesday . The stock traded as low as $9.99 and last traded at $10.14. Approximately 93,545 shares changed hands during trading, a decline of 2% from the average daily volume of 95,250 shares. The stock had previously closed at $11.14.

Coeptis Therapeutics Stock Performance

The company has a debt-to-equity ratio of 0.01, a current ratio of 3.25 and a quick ratio of 3.25. The firm has a fifty day simple moving average of $11.95 and a 200 day simple moving average of $13.26. The company has a market cap of $544.64 million, a price-to-earnings ratio of -4.20 and a beta of -0.22.

Coeptis Therapeutics (NASDAQ:ZSQR) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($0.65) EPS for the quarter. Coeptis Therapeutics had a negative net margin of 810.04% and a negative return on equity of 92.29%. The company had revenue of $0.11 million for the quarter.

Institutional Investors Weigh In On Coeptis Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Geode Capital Management LLC grew its position in shares of Coeptis Therapeutics by 12.6% in the fourth quarter. Geode Capital Management LLC now owns 42,097 shares of the company’s stock valued at $600,000 after purchasing an additional 4,721 shares during the last quarter. State Street Corp grew its stake in shares of Coeptis Therapeutics by 35.0% in the fourth quarter. State Street Corp now owns 26,830 shares of the company’s stock worth $382,000 after acquiring an additional 6,962 shares during the last quarter. Marshall Wace LLP acquired a new stake in Coeptis Therapeutics during the fourth quarter worth about $259,000. Yorkville Advisors Global LP acquired a new stake in Coeptis Therapeutics during the third quarter worth about $140,000. Finally, Steward Partners Investment Advisory LLC grew its position in Coeptis Therapeutics by 100.0% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 5,000 shares of the company’s stock worth $71,000 after buying an additional 2,500 shares in the last quarter. 13.88% of the stock is owned by institutional investors and hedge funds.

Coeptis Therapeutics Company Profile

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.